Sylvester Comprehensive Cancer Center at University of Miami Purchases Varian ProBeam Compact Proton Therapy System
PALO ALTO, Calif., Jan. 25, 2018 /PRNewswire/ -- Highlighting the growing adoption of proton therapy systems for the treatment of cancer, Varian (NYSE: VAR) today announced it has reached an agreement with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine for the purchase and installation of a Varian ProBeam® Compact proton therapy system. The system is scheduled to be installed at Sylvester, part of the University of Miami Health System, in early 2019 and begin patient treatments in the first half of 2020. In addition to the equipment, Varian will also provide its ARIA® information management system and Eclipse™ treatment planning system.
The Varian ProBeam Compact system is the only single room system capable of fully rotational intensity modulated proton therapy (IMPT). Treatments can be delivered with an unmatched combination of speed, flexibility and cost efficiency. The full-featured ProBeam Compact includes a cyclotron, Varian's unique Dynamic Peak™ scanning technology for intensity modulated proton therapy (IMPT), a fully rotational gantry, robotic patient positioning tools, and a comprehensive suite of motion management tools. It includes integrated cone beam CT imaging for positioning the patient based on high quality anatomical images with excellent soft tissue resolution.
"In selecting a proton therapy system, we wanted a company that understood our mission to put proven technology in the hands of our highly skilled radiation oncologists for the benefit of our patients," said Dr. Stephen D. Nimer, director of Sylvester.
Dr. Alan Pollack, chair of radiation oncology and interim deputy director of Sylvester, said, "We look forward to the installation of our ProBeam Compact system and incorporating it into our robust clinical research programs and our multidisciplinary cancer care."
"By expanding our partnership with Sylvester Comprehensive Cancer Center to now include proton therapy, we are able to showcase the synergies of our broad cancer care portfolio," said Dr. Moataz Karmalawy, general manager of Varian's Particle Therapy division. "Florida is developing as the leading region in proton therapy with 7 centers operating or under construction in the state. We look forward to continuing this partnership and making this advanced cancer fighting technology available to more patients in Florida."
Varian booked the order for the equipment in the first quarter of its fiscal year 2018. Varian is also working on proton therapy system installations at 18 other sites around the world.
For more information on ProBeam and its Compact single-room configuration, visit: www.varian.com/probeamcompact
About Varian
Varian is a leader in developing and delivering cancer care solutions, and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Press Contact
Mark Plungy
Director, Public Relations
+1 (650) 424-5630
[email protected]
Investor Relations Contact
J. Michael Bruff
Vice President, Investor Relations
+1 (650) 424-5163
[email protected]
SOURCE Varian
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article